Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Akeso, Inc.
康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") at the request of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

The Company has noted the **press release** published by Summit Therapeutics Inc. (NASDAQ: SMMT) on November 15, 2026 regarding the Complete Response Letter ("**CRL**") received from the United States Food and Drug Administration for ivonescimab's Biologics License Application based on HARMONi Study.

Having made such enquiry with respect to the Company as is reasonable in the circumstances, we confirm that save for the CRL which might have caused the unusual price movements of the shares of the Company, we are not aware of any reasons for the price movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to disclosed under Part XIVA of the Securities and Futures Ordinance.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive Director

Hong Kong, November 16, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.